The Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market pertains to the region's healthcare sector, focusing on treating AATD, a rare genetic disorder affecting the lungs and liver. Augmentation therapy is a treatment approach that involves administering Alpha-1 antitrypsin protein to patients to mitigate symptoms and improve lung function. Market players, including pharmaceutical companies, are investing in research and development to develop more effective therapies, fostering better quality of life for AATD patients in Europe.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/europe-alpha-1-antitrypsin-deficiency-aatd-augmentation-therapy-market
Data Bridge Market Research analyses that the Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market is expected to grow at a CAGR of 8.3% in the forecast period of 2022 to 2029 and is expected to reach USD 317.65 million by 2029 from 179.24 million in 2021. Europe's increasing elderly population heightens vulnerability to AATD, amplifying the need for advanced treatment solutions. This demographic shift intensifies demand for therapies, emphasizing innovative medical interventions' crucial role in addressing the specific healthcare requirements of the aging populace affected by alpha-1 antitrypsin deficiency.
Key Findings of the Study
Rising healthcare expenditure is expected to drive the market's growth rate
Increasing healthcare budgets and government initiatives in Europe nations have offered substantial financial backing for AATD treatment options. This expanded healthcare expenditure is instrumental in ensuring that individuals affected by alpha-1 antitrypsin deficiency (AATD) can access and afford the necessary therapies, enhancing their quality of life and well-being. It reflects a commitment to addressing rare genetic disorders and underscores the importance of accessible and effective treatment for AATD patients in the region.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Prolastin, Aralast NP, Zemaira/Respreeza, Glassia And Others), Gene Type (Type Pimz, Type Pims, Type Pizz And Others), Application (Lung Disease And Liver Disease), Population Type (Adults And Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, And Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy And Others)
|
|
Countries Covered
|
Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey and Rest of Europe.
|
|
Market Players Covered
|
Grifols, S.A. (Spain), CSL (Australia), Kamada Pharmaceuticals (Israel), Takeda Pharmaceutical Company Limited: (Japan), LFB BIOMEDICAMENTS (France), Arrowhead Pharmaceuticals, Inc. (U.S.), Mereo BioPharma Group plc (U.K), Inhibrx, Inc. (U.S.), Centessa Pharmaceuticals (Z Factor) (U.S.), Intellia Therapeutics, Inc. (U.S.), Apic Bio (U.S.), Krystal Biotech (U.S.), Beam Therapeutics (U.S.), LOGICBIO THERAPEUTICS, INC. (U.S.).
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into drugs, gene type, application, population type, end user, and distribution channel
- On the basis of drugs, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into prolastin, aralast NP, zemaira/respreeza, glassia and others
- On the basis of gene type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into type PiMZ, type PiMS, type PiZZ and others
- On the basis of application, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into lung disease and liver disease
- On the basis of population type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into adults and pediatric
- On the basis of end user, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospitals, specialty clinics, home healthcare, and others
- On the basis of distribution channel, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others
Major Players
Data Bridge Market Research recognizes the following companies as the major Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market players in Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market are Grifols, S.A. (Spain), CSL (Australia), Kamada Pharmaceuticals (Israel), Takeda Pharmaceutical Company Limited: (Japan), LFB BIOMEDICAMENTS (France), Arrowhead Pharmaceuticals, Inc. (U.S.), Mereo BioPharma Group plc (U.K), Inhibrx, Inc. (U.S.), Centessa Pharmaceuticals (Z Factor) (U.S.).
Market Developments
- In May 2023, Biogen and a leading European biopharmaceutical firm announced a strategic collaboration to develop an innovative AATD augmentation therapy. This partnership aims to combine their expertise in biotechnology to advance treatment options for Alpha-1 Antitrypsin Deficiency, addressing unmet medical needs and expanding the market potential
- In March 2023, Biogen and AstraZeneca announced a strategic collaboration to develop a novel Alpha-1 Antitrypsin Deficiency (AATD) augmentation therapy. This collaboration aims to leverage their respective expertise and resources to advance the treatment options for AATD patients, promising significant advancements in the field
- In June 2021, Kamada Ltd., a leading biopharmaceutical company, announced a strategic collaboration with Takeda Pharmaceutical Company Limited. The collaboration aimed to develop an innovative plasma-derived therapy for Alpha-1 Antitrypsin Deficiency. This partnership leveraged Takeda's expertise and Kamada's advanced technology, promising advancements in AATD treatment, enhancing patient outcomes, and driving market growth
- In March 2021, Grifols announced its collaboration with Kamada to develop a new Alpha-1 Antitrypsin Deficiency (AATD) therapy. This partnership aims to leverage Kamada's expertise in plasma-derived products and Grifols' extensive experience in treating AATD to provide more effective treatment options for patients in the future
- In October 2020, Takeda Pharmaceutical Company Limited revealed a partnership with Arrowhead Pharmaceuticals Inc. for the advancement of ARO-AAT, a Phase 2 investigational RNA interference therapy designed to address alpha-1 antitrypsin-associated liver disease (AATLD) within the Europe AATD augmentation therapy market
Regional Analysis
Geographically, the countries covered in the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report are Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey and Rest of Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant region in Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market during the forecast period 2022-2029
Germany dominates the European AATD augmentation therapy market, driven by substantial market share and revenue. The sustained dominance is attributed to Germany's robust healthcare spending, which surpasses other EU member states, strengthening its market expansion during the forecast period.
For more detailed information about the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report, click here – https://www.databridgemarketresearch.com/fr/reports/europe-alpha-1-antitrypsin-deficiency-aatd-augmentation-therapy-market
